Minhua Chu, Managing Partner at Transition Value Partner, shared a post on X:
“ETERN Therapeutics announced completion of its B2 equity financing, led exclusively by Guangzhou Biomedical and Health Industry Investment.
The company focuses on LLPS‑targeted small‑molecule therapeutics, a frontier approach for previously ‘undruggable’ protein targets. ETERN’s first‑in‑class anti‑pathologic‑scar candidate ETD‑001 has now advanced into the clinical stage.
The company previously formed a deep strategic alliance with Insilico Medicine, building an integrated AI‑driven biology + LLPS small‑molecule innovation framework and entering the fast‑growing global skin anti‑aging market.”
Other articles featuring Minhua Chu on OncoDaily.